Related Experiment Video
Updated: Jul 14, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Fabry disease model: a rational approach to the management of Fabry disease
1University of Würzburg, Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany. wanner_c@medizin.uniwuerzburg.de
Abstract:
Fabry disease (FD) is a truly progressive, multisystemic disorder. Clinically, the disease will present with 2 different faces throughout the lifetime of a patient: peripheral neurologic involvement predominates the symptoms in the first 3 decades of life (early symptoms), whereas major clinical events in the kidneys and heart or cerebrovascular system (late complications) largely determine the morbidity and mortality after 30 years of age. Before clinical manifestations occur in any organ system, there appears to be an insidious, subclinical progression of disease activities in various organ systems. Different stages of disease progression are associated with varying prognoses and potential responses to therapy, which provide a strong rationale for early intervention. Different stages may also be associated with various secondary pathologic events, which can provide indications for the use of a combination of interventions meant to control the primary pathology (lysosomal storage) as well as modifiable pathologies or correctable failures. A rational approach to FD and the therapy options available may help determine treatment choices and define therapeutic objectives as a function of optimal health outcomes, adequately reflecting the actual stage of disease progression, in individual patients.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
